Personalized patient care with aggressive hematological malignancies in non-responders to first-line treatment
Author:
Affiliation:
1. Tumor Center, Nihon University Itabashi Hospital, 173-8610, Itabashi city, Japan
2. Department of Hematology and Rheumatology, Nihon University School of Medicine, 173-8610, Itabashi city, Tokyo, Japan
Publisher
Informa UK Limited
Subject
Drug Discovery,Pharmacology,Genetics,Molecular Medicine
Link
https://www.tandfonline.com/doi/pdf/10.1080/23808993.2021.1903314
Reference124 articles.
1. Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial
2. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
3. Prediction of CR following a second course of ‘7+3’ in patients with newly diagnosed acute myeloid leukemia not in CR after a first course
4. Gilteritinib for the treatment of patients withFLT3mutated relapsed or refractory acute myeloid leukemia
5. Availability of FLT3 inhibitors: how do we use them?
Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Pirarubicin‐based intensive chemotherapy followed by consolidative high‐dose chemotherapies for peripheral T‐cell lymphomas: A noncomparative phase 2 study;Hematological Oncology;2022-07-08
2. Malignant Lymphoma:;Journal of Nihon University Medical Association;2022-04-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3